🔗 Share this article

Given that the US undertakes sweeping revisions to its immunization recommendations, one figure appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus shots throughout the pandemic and has zeroed in on potential fatalities after Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Schedule

Agency leaders were set to unveil major changes to the childhood vaccine schedule in December, aligning the US with Denmark’s national calendar, according to reports – a major change that would place the US out of alignment with a large portion of the global community with insufficient data for benefit. This reveal has been pushed back until the new year.

In place of Vinay Prasad, Høeg is listed to speak at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A Shift at the FDA

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

Høeg has repeatedly called for ending specific childhood immunization guidelines in the US so as to align more like the Danish model, a society with universal health coverage and a population roughly the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Concerns Over Qualifications

Høeg has no apparent background in medication creation, oversight or management, which has been typical for previous heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have the necessary background” for running the CDER, said Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Previous directors of the center would “understand regulatory frameworks and the science of drug development”, noted Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who ran CBER have had.”

CDER has an vast range of responsibilities at the agency, Woodcock emphasized.

“Many people just focuses on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and more, and each of these have to be managed,” she noted. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant management aspect to the role, which manages in excess of 5,000 staff members. “It’s a enormous administrative position, if you do it right,” the former official said.

Official Statement and Controversial Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment indicates greater collaboration among agency officials on immunizations, a press secretary stated that the “questions are based on incorrect presumptions”.

“Her experience aligns with the duties of her role,” the official explained, citing the time Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a contentious rapid medication authorization process that allegedly troubled her predecessors. “How are these drugs being chosen for this voucher program? Who takes the choices?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards more relaxed oversight of most medications, except for shots.”

Public History on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, past, some experts have noted. She released a analysis using non-validated public submissions to estimate the rate of heart inflammation after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new federal leadership featured changing rules for new vaccines and ending “non-essential” immunizations, she said after the election on a audio program. At the FDA, Høeg has reportedly proposed excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who starts off with her beliefs and reverse-engineers to fit the evidence in a extremely deceptive, dishonest way,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|